Reuters logo
Medivation, Astellas seek to market prostate cancer drug in Europe
June 26, 2012 / 11:26 PM / in 5 years

Medivation, Astellas seek to market prostate cancer drug in Europe

TOKYO, June 27 (Reuters) - Medivation Inc and Astellas Pharma Inc said on Wednesday they have submitted to European health authorities an application to market enzalutamide, a drug for prostate cancer in patients previously treated with chemotherpy.

The two companies had last month aubmitted a new drug application for enzalutamide in the United States.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below